STOCK-BASED COMPENSATION |
NOTE
7 – STOCK-BASED COMPENSATION
Stock
Options:
The
following table summarizes stock option-based compensation for the three and nine months ended September 30, 2020 and 2019:
SCHEDULE OF STOCK BASED COMPENSATION
|
|
For
the three months ended September 30, |
|
|
For
the nine months ended September 30, |
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Research and development |
|
$ |
765,000 |
|
|
$ |
972,000 |
|
|
$ |
2,380,000 |
|
|
$ |
3,013,000 |
|
General and administrative |
|
|
484,000 |
|
|
|
854,000 |
|
|
|
1,703,000 |
|
|
|
2,594,000 |
|
Stock option-based compensation expense
included in operating expense |
|
|
1,249,000 |
|
|
|
1,826,000 |
|
|
|
4,083,000 |
|
|
|
5,607,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stock option-based compensation
expense |
|
|
1,249,000 |
|
|
|
1,826,000 |
|
|
|
4,083,000 |
|
|
|
5,607,000 |
|
Tax benefit |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock option-based
compensation expense, net of tax |
|
$ |
1,249,000 |
|
|
$ |
1,826,000 |
|
|
$ |
4,083,000 |
|
|
$ |
5,607,000 |
|
Stock Option [Member]
We
estimate the fair value of each option award on the date of grant using the Black-Scholes option valuation model. We then recognize
the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service
period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:
|
● |
Expected
volatility – we estimate the volatility of our share price at the date of grant using a “look-back” period
which coincides with the expected term, defined below. We believe using a “look-back” period which coincides with
the expected term is the most appropriate measure for determining expected volatility. |
|
● |
Expected
term – we estimate the expected term using the “simplified” method, as outlined in Staff Accounting Bulletin
No. 107, “Share-Based Payment.” |
|
● |
Risk-free
interest rate – we estimate the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the
expected term of the options in effect at the time of grant. |
|
● |
Dividends
– we use an expected dividend yield of zero because we have not declared or paid a cash dividend, nor do we have any
plans to declare a dividend. |
We
used the following weighted-average assumptions to estimate the fair value of the options granted for the periods indicated:
SCHEDULE OF WEIGHTED-AVERAGE ASSUMPTIONS TO ESTIMATE THE FAIR VALUE OF THE OPTIONS GRANTED
|
|
For
the three months ended September 30, |
|
|
For
the nine months ended September 30, |
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Expected volatility |
|
|
110% |
|
|
|
103% |
|
|
|
111% |
|
|
|
108% |
|
Expected term |
|
|
6.25
years |
|
|
|
6.25
years |
|
|
|
6.25
years |
|
|
|
5.09
years |
|
Risk-free interest rate |
|
|
0.16% |
|
|
|
1.83% |
|
|
|
0.29% |
|
|
|
2.21% |
|
Expected dividend yield |
|
|
0% |
|
|
|
0% |
|
|
|
0% |
|
|
|
0% |
|
The
following table summarizes the options granted for the periods indicated:
SCHEDULE OF OPTIONS ACTIVITY
|
|
For
the three months ended September 30, |
|
|
For
the nine months ended September 30, |
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Options granted |
|
|
342,100 |
|
|
|
105,600 |
|
|
|
3,415,146 |
|
|
|
1,490,490 |
|
Weighted-average: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise price |
|
$ |
3.08 |
|
|
$ |
2.58 |
|
|
$ |
2.38 |
|
|
$ |
6.53 |
|
Grant date fair value |
|
$ |
2.56 |
|
|
$ |
2.09 |
|
|
$ |
1.99 |
|
|
$ |
5.14 |
|
Restricted
Common Stock:
The
following table summarizes restricted common stock compensation expense for the three and nine months ended September 30, 2020
and 2019:
SCHEDULE OF STOCK BASED COMPENSATION
|
|
For
the three months ended September 30, |
|
|
For
the nine months ended September 30, |
|
|
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
Research and development |
|
$ |
89,000 |
|
|
$ |
66,000 |
|
|
$ |
561,000 |
|
|
$ |
66,000 |
|
General and administrative |
|
|
72,000 |
|
|
|
32,000 |
|
|
|
251,000 |
|
|
|
282,000 |
|
Restricted stock-based compensation
expense included in operating expense |
|
|
161,000 |
|
|
|
98,000 |
|
|
|
812,000 |
|
|
|
348,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total restricted stock-based compensation
expense |
|
|
161,000 |
|
|
|
98,000 |
|
|
|
812,000 |
|
|
|
348,000 |
|
Tax benefit |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Restricted stock-based
compensation expense, net of tax |
|
$ |
161,000 |
|
|
$ |
98,000 |
|
|
$ |
812,000 |
|
|
$ |
348,000 |
|
We
granted 818,233 shares of restricted common stock, net of cancellations, during the nine months ended September 30, 2020. There
were 265,080 shares of restricted common stock canceled during the three months ended September 30, 2020. We granted 376,625 shares
of restricted common stock during the three and nine months ended September 30, 2019.
|